Regulatory Submission Clause Samples
The Regulatory Submission clause outlines the obligations of parties to prepare, file, and maintain necessary documents with regulatory authorities to obtain approvals or comply with legal requirements. Typically, this clause specifies which party is responsible for submitting applications, responding to regulatory inquiries, and providing updates on the status of submissions. Its core function is to ensure that all required regulatory processes are handled efficiently and in compliance with applicable laws, thereby facilitating the timely progression of the underlying transaction or project.
Regulatory Submission. It is understood and acknowledged by the Parties that positive Clinical Data could be used to obtain label changes for the Compounds, and each Party may propose a Subsequent Study (as defined below) in connection therewith in accordance with Section 3.14.
Regulatory Submission. It is understood and acknowledged by the Parties that positive Clinical Data may be used to [***].
Regulatory Submission. 3.1.1 Eyemax shall own any Registrations for Product and hereby grants to Eton exclusive rights under all such Registrations.
3.1.2 Eyemax shall be responsible for submission of all initial Regulatory Filings to obtain Registration for Product at its own expense. For purposes of clarity, the preceding sentence only covers the NDA filing fee only. Subject to the foregoing, Eton shall take all reasonably necessary actions to support and obtain Registration thereafter by performing such development and obtaining such data and information as reasonably necessary therefor at its own expense. Without limiting and subject to the foregoing, Eton shall have the right to prepare, file, prosecute, submit and control all Regulatory Filings for Product. Eyemax shall provide to Eton all reasonable assistance as Eton may request from time to time in connection therewith. Eton shall provide to Eyemax reasonably requested updates as to the Registration and Regulatory Filings as Eyemax may request from time to time.
3.1.3 Eyemax hereby appoints Eton as Eyemax’s authorized representative, agent and attorney in fact to pursue and maintain Registration of Product. Eton hereby accepts such appointment. Without limiting the foregoing, Eton shall have the exclusive right, subject to the first sentence of Section 3.1.2, (a) to submit relevant Regulatory Filings; (b) to interact and communicate with the FDA and other regulatory authorities in the Territory regarding Regulatory Filings and Registration of Product; (c) to collect information on the adverse effects of Product and report the same to the FDA; and (d) to coordinate and control any Recall (as defined below) of Product in accordance with this Agreement and applicable laws and regulations and reporting relevant information to the FDA.
3.1.4 Without limiting anything set forth herein, Eyemax shall reasonably assist, execute such certificates and other instruments and otherwise cooperate with Eton in connection with any Regulatory Filings as necessary to permit the promotion, marketing and sale of Product in the Territory and comply with all Registration requirements therein.
Regulatory Submission. It is understood and acknowledged by the Parties that positive Clinical Data could be used to obtain label changes for the Compounds. In such event, the Parties will enter into good faith negotiations to determine a regulatory submission strategy for the Compounds [*].
Regulatory Submission. Aptalis shall be responsible for fulfilling Spontaneous AE reporting obligations to the Competent Authorities or Regulatory Agency in the Territory and Strakan shall be responsible for fulfilling Spontaneous AE reporting obligations to the Competent Authorities or Regulatory Agency outside the Territory. Strakan and Aptalis will make every effort to ensure that their respective partners are accountable for the regulatory submission where neither Party is the MA holder for the Subject Product.
Regulatory Submission. To the extent required by Law, and within 30 days after the Effective Date of this Agreement, Supplier, its Subcontractors and/or any Managed Third Party Telecom Transport Provider shall file any applicable tariff, tariff option or other regulatory submission required to implement the Agreement. Such filing shall be consistent in all material respects with all applicable provisions of this Agreement and shall not be less favorable to Kraft and the Eligible Recipients than the rates and other terms and conditions of this Agreement. Supplier shall make a copy of any applicable filings available to Kraft for Kraft’s review and inspection and shall provide Kraft with a copy of all amendments to such tariffs or other filings having a bearing on the Agreement when such amendments are filed with the appropriate governmental agencies. In addition, Supplier shall provide a draft of any revisions that may substantively affect Kraft’s rights and obligations under this Agreement at least 10 days before such revisions are filed with and Applicable Regulatory Authority, where feasible. If Supplier, its Subcontractors and/or any Managed Third Party Telecom Transport Provider makes revisions to a tariff, tariff option or other submission that materially and adversely affect Kraft’s rights hereunder without obtaining Kraft’s prior written consent, Kraft shall have the right to terminate any affected portions of this Agreement without payment of Termination Charges or other liability.
Regulatory Submission a submission to the appropriate regulatory agency in any one of the United States or the European Union of a properly completed application (together with all required supplementary materials and supporting data) meeting all applicable requirements for approval that, if approved by the agency, would permit commercialization of the plant product without filing any additional applications or submitting any additional supporting data or other supplemental materials. If the submission meets the requirements set forth above, then whether or not the agency approves of the plant product is not relevant in determining whether Regulatory Submission has been achieved. If no Regulatory Submission is required, then the plant product shall be deemed to have achieved Regulatory Submission if it has been commercially sold.
Regulatory Submission. At the appropriate time, Scopus Biopharma plans to file a pre-IND meeting request with FDA to confirm that the planned CMC and non-clinical tasks will support the initiation of the proposed Phase 1 clinical trials. In this way, course corrections in the development plan can be made early on, expediting development and avoiding waste of resources.
Regulatory Submission. PDTI shall be responsible for preparing and filing in its own name any IDE or IND which may be necessary for conducting Clinical Tests of SnET2 Light Devices. PDTI shall be responsible for preparing and submitting PMAs or other regulatory submissions for SnET2 Light Devices;, except in those countries where PMAs are not independent from an NDA for SnET2, in which case P&U shall have primary responsibility for the submission. All regulatory submissions for SnET2 Light Devices shall be filed in the name of, and shall remain the sole and exclusive property of PDTI, except in such countries which require that regulatory approvals be held by the distributor in such country. Each party shall provide the other with copies of all regulatory submissions. If any information is submitted to the FDA directly by the Light Device Provider or other third party, P&U shall be granted rights of reference or other rights to such submissions adequate for it to comply with all regulatory requirements. P&U shall be responsible for, and PDTI shall cooperate with, securing government or private price approvals and reimbursement qualifications in preparation for product launch of SnET2 Light Devices (other than SnET2 Light Sources).
Regulatory Submission. To the extent required by Law, and within thirty (30) days after the Effective Date, Service Provider shall, and shall use commercially reasonable efforts to, cause its Subcontractors and/or any Managed Telecom Transport Provider to, file any applicable tariff, tariff option or other regulatory submission required to implement this Agreement. Service Provider shall cause such filing to be consistent in all material respects with all applicable provisions of this Agreement and not to be less favorable to Allegheny and the Eligible Recipients than the rates and other terms and conditions of this Agreement. Service Provider shall make a copy of any applicable filings available to Allegheny for Allegheny’s review and inspection and shall provide Allegheny with a copy of all amendments to such tariffs or other filings having a bearing on the Agreement when such amendments are filed with the appropriate governmental agencies. In addition, Service Provider shall provide Allegheny with a draft of any revisions that will materially affect Allegheny’s rights and obligations under this Agreement at least ten (10) days before such revisions are filed with an Applicable Regulatory Authority, where feasible. Without limiting Allegheny’s termination rights provided elsewhere in this Agreement, if Service Provider, its Subcontractors and/or any Managed Telecom Transport Provider makes revisions to a tariff, tariff option or other submission that materially and adversely affect Allegheny’s rights hereunder without obtaining Allegheny’s prior written consent, Allegheny shall have the right to terminate any affected telecom portions of the Services ***.